Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The company said it ultimately plans to use the liquidity from the credit facility to fund a portion of its pending $4 billion acquisition of Cepheid.
The $4 billion acquisition is now cleared in the US, Germany, Austria, and South Africa.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
Phenomenex, a privately held manufacturer of consumables for the separation sciences, will operate as a standalone business and will retain its brand.
Danaher expects shareholders will see returns from the acquisition in the fifth year, as post-acquisition cost savings and revenues kick in.
Trichomonas is a nonviral sexually transmitted disease caused by infection with the protozoan parasite Trichomonas vaginalis.
Danaher said that it expects the acquisition to be accretive to earnings in the fifth full year post acquisition.
Danaher Q2 net earnings fell 5 percent to $656.7 million, or $.94 per diluted share, from $695.7 million, or $.97 per diluted share, a year ago.